Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407081 | 0.89 | ALDH1A1 (0.86) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL6029674 | 0.85 | ALDH1A1 (1.00) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL4432052 | 0.77 | ALDH1A1 (0.76) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL20457664 | 0.77 | ALDH1A1 (0.77) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL6404693 | 0.76 | BDKRB1 (0.78) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL4424964 | 0.74 | ALDH1A1 (0.76) | POLBALDH1A1BDKRB1MAPTGAA | |
| SCHEMBL6408196 | 0.73 | ALDH1A1 (0.71) | POLBALDH1A1BDKRB1MAPTMAPK1 | |
| SCHEMBL6030107 | 0.73 | BDKRB1 (0.48) | POLBALDH1A1BDKRB1 | |
| SCHEMBL4420787 | 0.72 | BDKRB1 (0.63) | POLBALDH1A1BDKRB1KDM4E | |
| SCHEMBL5566131 | 0.72 | BDKRB1 (0.63) | POLBALDH1A1BDKRB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | claimed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | POLB 2903/4885ALDH1A1 3743/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.